CN104274583A - Tibetan medicinal preparation for treating essential hypertension and preparation method thereof - Google Patents
Tibetan medicinal preparation for treating essential hypertension and preparation method thereof Download PDFInfo
- Publication number
- CN104274583A CN104274583A CN201410515691.9A CN201410515691A CN104274583A CN 104274583 A CN104274583 A CN 104274583A CN 201410515691 A CN201410515691 A CN 201410515691A CN 104274583 A CN104274583 A CN 104274583A
- Authority
- CN
- China
- Prior art keywords
- preparation
- lagotis
- weight portion
- song sheng
- medicinal preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a Tibetan medicinal preparation for treating essential hypertension. The Tibetan medicinal preparation for treating the essential hypertension is prepared from the following raw medicinal materials in parts by weight: 100-200 parts of Tibetan caragana, 50-150 parts of Adhatoda Vasica Nees, 50-150 parts of Herba Lagotis, 50-150 parts of corydalis pygmaea, 50-150 parts of lignum rhamnellae ointment or 500-1500 parts of lignum rhamnellae and 80-180 parts of phyllanthus emblica. The Tibetan medicinal preparation for treating the essential hypertension has the effects of treating the essential hypertension and lowering blood pressure and can be used for preparing an antihypertensive drug.
Description
The application is the divisional application of the Chinese patent application 201210290142.7 that on August 15th, 2012 submits to.
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Tibetan medicinal preparation with hypotensive effect and preparation method thereof.
Background technology
Hypertension refers to that the cause of disease is not yet clear and definite, a kind of independent disease being main clinical manifestation higher than normal range with systemic arterial blood pressure.Hypertension be a kind of with arterial pressure rising for feature, can with the systemic disease of the functional or organic change of heart, blood vessel, brain and kidney and other organs, it have essential hypertension and secondary hypertension point.Essential hypertension is called hypertension again, be with blood pressure rising for main clinical manifestation and the independence disease of etiology undetermined, account for hypertensive patient's more than 90%.Secondary hypertension is called symptomatic hypertension again, clear and definite in the hypertensive cause of disease of this apoplexy due to endogenous wind, is one of performance of certain disease.The reason of hypertension incidence is a lot, can be divided into h and E two aspects.Chinese medicine is thought, human five internal organs's six internal organs have corresponding projection on foot, and foot is the starting point of Three Yin Channels of Foot, is again the terminating point of the three yang channels of foots, just has more than 60 acupuncture point below ankle joint.
The early symptom of hypertension is dizziness, headache, cardiopalmus, insomnia, anxiety, agitation, tired etc.The heart, brain, kidney organ can be involved gradually, the pathological changes such as Complicated with Hypertension heart disease, renal failure, cerebrovas-cularaccident time serious later.
The cause of disease and the pathogenesis of hypertension are as described below, the wherein cause of disease: the 1) age: sickness rate has the trend increased with age growth, and within more than 40 years old, person's sickness rate is high.2) Sal: take in Sal many persons, Hypertension incidence is high, has and thinks and Sal <2g/ day hardly hypertension occurs; 3-4g/ day, 3%, 4-15g/ day of Hypertension incidence, 33.15%, >20g/ day of sickness rate sickness rate 30%.3) body weight: overweight people's sickness rate is high.4) heredity: approximately half hyperpietic has family history.5) environment and occupation: the working environment having noise, overwrought mental work all easily hypertension occurs, and the high pressure sickness rate in city is higher than rural area.
Pathogenesis: 1) talk about from modal overweight people's hypertension, too fat hyperliposis, certain extruding is caused to blood vessel, after pipeline is extruded, power source needs to strengthen power just may make original circulation reach circulation, power source power strengthens, and pipeline pressure also can strengthen thereupon, just defines high pressure.2) thrombosis that internal blood and other diseases cause causes, the metabolism of blood, discharges thorough not, forms dirt, cause certain blocking, pressure can be made to raise to pipeline at pipe interior.3) senile pipeline sclerosis and disease sclerosis, pipeline gives a discount and hardens, and can cause high pressure.4) disease blood capillary blocking and the blocking of traumatic blood capillary, be also one of factor wherein.5) body disease causes, a part of hyperglycemic patients, is because digestive system is too excited, in the intestines and stomach, has pathological changes, will form certain blood circulation blocking, also can cause high pressure in the intestines and stomach body.6) the congenital and posteriori disappearance of heart aspect.7) cerebrovascular disease causes.8) blood dries up the high pressure caused.
Depressor plays pressure reduction effect mainly through the system that affects the physiological regulation to blood pressure such as sympathetic nervous system, renin angiotensin aldosterone system and endothelin system and play an important role.Conventional depressor has: sympathetic nerve depressant is as fixed in clonidine, guanidine second, prazosin, Propranolol etc.; The depressor of major effect blood volume is as hydrochlorothiazide; Tonin inhibitor is as captopril; Angiotensin receptor antagonist (ARB) is as Candesartan; Calcium antagonists is if nifedipine and direct vasodilator smooth muscle medicine are as hydralazine etc.
Hypertensive Drug therapy is generally take Western medicine and Chinese medicine two kinds of Therapeutic Method.The principle of Western medicine blood pressure lowering is generally by blood vessel dilating by force, increase the effect that the means such as cardiac contractile force reach blood pressure lowering, but Western medicine depressor shortcoming has side effect, and the internal organs in side effect meeting major injury human body, especially liver, kidney, so hypertensive patient can not depending on western medicine completely.Although Traditional Chinese Medical on Treating Hypertension drug effect is slow, the course for the treatment of is longer, is treating both the principal and secondary aspects of a disease.Hypertension worldwide still belongs to a difficult problem, also cannot effect a radical cure at present, and thus hyperpietic needs to control blood pressure by Long-term taking medicine, thus should select gentleness, slowly, the Chinese medicine that lasting, side effect is little, just can not bring infringement to health.
Chinese patent application CN102590430A discloses a kind of detection method of liuwei caragana preparation, is made up of Cortes seu Caulis Caraganae jubatae, Radix Inulae, Fructus Tsaoko, Fructus Amomi Rotundus, Semen Arecae, Rhizoma Alpiniae Officinarum Six-element medicine.Wherein each primary raw material medicine is as follows:
Cortes seu Caulis Caraganae jubatae: record " the Sanitation Ministry medicine standard " (Tibetan medicine first), this product is the woody part heartwood of leguminous plant Cortes seu Caulis Caraganae jubatae Caragana jubata (pall.) Poir. and Changdu caragana Caraganachangduensis fiauf.Cut and get maroon woody part, cut off, dry in the shade.
Radix Inulae: record in " Chinese Pharmacopoeia " 2010 editions, annex 27 pages is the dry root of feverfew total shape Radix Aristolochiae Inula racemosa Hook.f..Uproot with autumn end at the beginning of spring, remove residual stem, earth, section, dries.
Fructus Tsaoko: record " Chinese Pharmacopoeia " version in 2010, the 222nd page, this product is the dry mature fruit of zingiberaceous plant Fructus Tsaoko Amomum tsao-ko Crevost et Lemaire.Gather during fruit maturation in autumn, removing impurity, dries or cold drying.
Fructus Amomi Rotundus: record " Chinese Pharmacopoeia " version in 2010, the 156th page, this product is the dry mature fruit of zingiberaceous plant Fructus Amomi Rotundus Amomum Kravanh Pierre ex Gagnep. or amomum compactum Soland ex Maton Amomum compactum Soland ex Maton.Be divided into " former Fructus Amomi Rotundus " and " the white bandit of Indonesia " by place of production difference.
Semen Arecae: record " Chinese Pharmacopoeia " version in 2010, the 342nd page, this product is the dry mature seed of babassu Semen Arecae Areca catechu L..Gather at the beginning of spring Mo to autumn mature fruit, after decocting in water, dry, removing peel, takes out seed, dry.
Rhizoma Alpiniae Officinarum: record " Chinese Pharmacopoeia " version in 2010, the 270th page, this product is the dry rhizome of zingiberaceous plant Rhizoma Alpiniae Officinarum Alpinia of ficinarum Hance.Excavate at the beginning of autumn late summer, removing fibrous root and residual scale, clean, and cuts off, dry.
At present also not about the report of the Tibetan medicinal preparation containing said components for the preparation for the treatment of hypotensive effect medicine.
Summary of the invention
The object of the present invention is to provide the purposes of a kind of Tibetan medicinal preparation in preparation treatment essential hypertension medicine.
Tibetan medicinal preparation of the present invention is made up of cream, Fructus Phyllanthi Six-element medicines such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng, wherein:
ZANGJINJIER: record " the Sanitation Ministry medicine standard " (Tibetan medicine first), this product is the woody part heartwood of leguminous plant Cortes seu Caulis Caraganae jubatae Caragana jubata (pall.) Poir. and Changdu caragana Caraganachangduensis fiauf.Cut and get maroon woody part, cut off, dry in the shade.
BAXIAGA: record in " the local quality of medicinal material standard of Tibet Autonomous Region ", standard No. is XZ-BC-0001-2003, for the dry aerial parts of bloodroot C. racemosa Corydalis racemosa (Thunb.) pers, dry or cut off dry for subsequent use.
Lagotis clarkei Hook. F (Lagotis brevituba Maxim.): record " Chinese Pharmacopoeia " version in 2010, the 249th page, this product is the dry herb of goatweed short cylinder Radix Pecteilis susannae Lagotis brevituba Maxim.Summer, autumn two gather when season, the flowers are in blossom, and removing impurity, cleans, dry in the shade.
Herba Corydalis: record in " the Sanitation Ministry medicine standard " (Tibetan medicine first), standard number: WS3-BC-0114-95, this product is the dry herb of bloodroot Herba Corydalis Corydalis hendersonii Hemsl. (C.nepaiesis kitamura) and flat handle Herba corydalis racemosae C.mucionifera Maxim., summer has grubbed out, clean, dry in the shade.
Song Sheng etc.: this product is the desiccated wood of the Fructus Rhamni parvifoliae Rhamnus parvifolia Bunge of Rhamnaceae plant Rhamnella gilgitica Rhamnella gilgitica Mansf.et Melch..The whole year all can gather, and except debarking, the section of being sawn into, dries after riving.
Fructus Phyllanthi: record in " Chinese Pharmacopoeia " version in 2010, the 167th page, this product is the dry mature fruit of euphorbia plant Fructus Phyllanthi Phyllanthus emblica L..Winter gathers to during secondary spring fruit maturation, removing impurity, dry.
Tibetan medicinal preparation of the present invention, is made up of following crude drug: 30-200 weight portion, the Fructus Phyllanthi 80-180 weight portions such as cream 50-150 weight portion or Song Sheng such as ZANGJINJIER 100-200 weight portion, BAXIAGA 50-150 weight portion, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 50-150 weight portion, Herba Corydalis 50-150 weight portion, Song Sheng.
Further, above-mentioned preparation is made up of following crude drug: 50-150 weight portion, the Fructus Phyllanthi 100-150 weight portions such as cream 80-120 weight portion or Song Sheng such as ZANGJINJIER 120-180 weight portion, BAXIAGA 80-120 weight portion, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 80-120 weight portion, Herba Corydalis 80-120 weight portion, Song Sheng.
Further, above-mentioned Tibetan medicinal preparation is made up of following crude drug: 100 weight portions, Fructus Phyllanthi 130 weight portions such as cream 100 weight portion or Song Sheng such as ZANGJINJIER 150 weight portion, BAXIAGA 100 weight portion, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 100 weight portion, Herba Corydalis 100 weight portion, Song Sheng.
Above-mentioned Tibetan medicinal preparation can be prepared into pharmaceutically acceptable preparation, as pill, tablet, capsule, oral liquid, syrup, granule, powder, drop pill, slow releasing preparation or controlled release preparation.
The experiment proved that, Tibetan medicinal preparation of the present invention has the effect for the treatment of essential hypertension and blood pressure lowering, more preferably, Tibetan medicinal preparation of the present invention reaches the effect of blood pressure lowering by reducing the systolic pressure of primary hypertension patient, diastolic pressure and mean arterial pressure, and then has therapeutical effect to essential hypertension.
Invention further provides the preparation method of above-mentioned Tibetan medicinal preparation, comprising:
By cream or the Song Sheng etc. such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng, the remove impurity respectively of Fructus Phyllanthi crude drug, cleaning, drying, be ground into coarse powder, sieve, mix and get final product.
The another kind of preparation method of Tibetan medicinal preparation of the present invention, comprise and cream or Song Sheng etc., the Fructus Phyllanthi crude drug such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng are carried out remove impurity, clean, mixing respectively, with 50-90% alcohol reflux 1-3 time of crude drug 5-15 times of weight, each extraction 0.5-2.5 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.0-1.5; Or extracting solution passed into absorption, washing, the flow velocity of resolving are 0.1-10 times of bed volume/hour D101 or D101B or XDA-1 or XDA-1B or HPD-300 macroporous adsorbent resin or cation exchange resin, first wash with water, again with 10-30% washing with alcohol, finally resolve with 50-70% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.0-1.5; Add the adjuvant pharmaceutically accepted, make described Tibetan medicinal preparation.
The another kind of preparation method of Tibetan medicinal preparation of the present invention, comprise cream or the Song Sheng etc. such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng, the remove impurity respectively of Fructus Phyllanthi medical material, clean, mix, stir with the 50-90% ethanol of crude drug 0.5-1.5 times of weight and infiltrate 0.5-2 hour, load in percolate pot, with 50-90% ethanol percolate extraction 2-4 time of crude drug 5-15 times of weight, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.0-1.5; Or extracting solution passed into absorption, washing, the flow velocity of resolving are 0.1-10 times of bed volume/hour D101 or D101B or XDA-1 or XDA-1B or HPD-300 macroporous adsorbent resin or cation exchange resin, first wash with water, again with 10-30% washing with alcohol, finally resolve with 50-70% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.0-1.5; Add the adjuvant pharmaceutically accepted, make described Tibetan medicinal preparation.
The another kind of preparation method of Tibetan medicinal preparation of the present invention, comprise cream or the Song Sheng etc. such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng, the remove impurity respectively of Fructus Phyllanthi medical material, clean, mix, extract 2-4 time by the 50-90% alcohol dipping of crude drug 5-15 times of weight, each dipping 8-16 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.0-1.5; Or extracting solution passed into absorption, washing, the flow velocity of resolving are 0.1-10 times of bed volume/hour D101 or D101B or XDA-1 or XDA-1B or HPD-300 macroporous adsorbent resin or cation exchange resin, first wash with water, again with 10-30% washing with alcohol, finally resolve with 50-70% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.0-1.5; Add the adjuvant pharmaceutically accepted, make described Tibetan medicinal preparation.
Another preparation method of Tibetan medicinal preparation of the present invention, comprise and cream or Song Sheng etc., the Fructus Phyllanthis such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng are carried out remove impurity, clean, mixing respectively, with soak by water 2-4 time of crude drug 5-15 times of weight, each decoction 0.5-2.5 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.0-1.5, add the adjuvant pharmaceutically accepted, make described Tibetan medicinal preparation.
The present invention adopts Tibetan medicine prescribed treatment essential hypertension, because Tibetan medicine generally grows on the snowy peak of height above sea level more than 3800 meter, so medicine does not have contaminated, the active ingredient of medicine is not subject to interference and the destruction of other material, so its drug effect also wants instant effect than Chinese medicine.The maximum feature that Tibetan medicine is cured the disease directly enters focus, directly suppresses virus, to get on treatment from body at all.In addition, the collection of Tibetan medicine is also different from Chinese medicine, and Chinese medicine and then goes season to gather, and Tibetan medicine gathers when medical material effective component content is the highest.So when treating essential hypertension, if Tibetan medicine crude drug can be adopted as the medicine for the treatment of essential hypertension, so will relatively reduce much the injury of human body.
Detailed description of the invention
Medicine source: medicine 1 (being prepared from according to embodiment in description 2) of the present invention, medicine 2 (being prepared from according to embodiment in description 3) of the present invention, medicine 3 (being prepared from according to embodiment in description 4) of the present invention, medicine 4 (being prepared from according to embodiment in description 6) of the present invention, medicine 5 (being prepared from according to embodiment in description 7) of the present invention, medicine 6 (being prepared from according to embodiment in description 8) of the present invention, medicine 7 (being prepared from according to embodiment in description 10) of the present invention, medicine 8 (being prepared from according to embodiment in description 11) of the present invention, medicine 9 (being prepared from according to embodiment in description 12) of the present invention, medicine 10 (being prepared from according to embodiment in description 14) of the present invention, medicine 11 (being prepared from according to embodiment in description 15) of the present invention, medicine 12 (being prepared from according to embodiment in description 16) of the present invention, pitchy is Powdered, thered is provided by XiZang QiZheng Tibetan pharmaceuticals Co., Ltd.Test the medicinal liquid that medicine 1-12 of the present invention is all made into 0.54g crude drug/10ml by front 0.5%CMC (hydroxy methocel), by 0.54g crude drug/kg administration, for rat oral gavage administrable, administration volume is 1ml/100g.
Animal origin: select satisfactory original hypertensive rat (SHR), 13 week age, male, body weight 220 ~ 250g.This especially big Mus (WKY) 12 of Tokyo prestige, 13 week age, as normal control, purchased from Beijing Vital River Experimental Animals Technology Co., Ltd., the animal quality certification number: SCXK (capital) 2006-0009.Rat feeding is indoor in constant temperature (22 ± 2 DEG C), and standard feed, freely drinks water.
Positive control medicine is originated: captopril: commercially available, specification 25mg/ sheet, and Tianjin Jinshi Pharmaceutical Co., Ltd. produces, and lot number 20100501, is mixed with 1.5mg/mL medicinal liquid with 0.5%CMC, and for rat oral gavage, administration volume is 1ml/100g.
Experiment reagent is originated: cholesterol (TC) test kit, and Zhongsheng Beikong Biological Science & Technology Co., Ltd. provides, lot number 100441.201004; Triglyceride (TG) test kit, Zhongsheng Beikong Biological Science & Technology Co., Ltd. provides, lot number 100441.201005; Low density lipoprotein, LDL (LDL) test kit, Zhongsheng Beikong Biological Science & Technology Co., Ltd. provides, lot number 100231.201004; High density lipoprotein (HDL) test kit, Zhongsheng Beikong Biological Science & Technology Co., Ltd. provides, lot number 100201.201005; Fibrinogen (Fbg) measures test kit, and the North Sea, Shanghai biotechnology Engineering Co., Ltd provides, lot number BH-25110.
Insulinase linked immunosorbent assay test kit (Mercodia Rat Insulin ELISA), MercodiaAb, Sylveniusgatan8A, SE-75450 Uppsala, Sweden provides, lot number 10-1124-01; Glucose (GLu) test kit, Zhongsheng Beikong Biological Science & Technology Co., Ltd. provides, lot number 100401.201004.
Superoxide dismutase (SOD) test kit, Nanjing is built up Bioengineering Research Institute and is provided; Lot number 20100403, specification 100 parts; Nitric oxide (NO) test kit, Nanjing is built up Bioengineering Research Institute and is provided, lot number 20100613, specification 100 parts; Malonaldehyde (MDA) test kit, Nanjing is built up Bioengineering Research Institute and is provided, lot number 20100613, specification 100 parts.
Plasma angiotensinogen II (AngII) radioimmunological kit, Beijing Mei Dike Bioisystech Co., Ltd provides, lot number HY-053; Plasma aldosterone (ALD) radioimmunological kit, Beijing Mei Dike Bioisystech Co., Ltd provides, lot number HY-054; Endothelin (ET) radioimmunological kit, Beijing Mei Dike Bioisystech Co., Ltd provides, lot number HY-040; Renin activity (PRL1) radioimmunological kit, Beijing Mei Dike Bioisystech Co., Ltd provides, lot number HY-134.
Pathology reagent: formalin, ethanol, dimethylbenzene, paraffin, dyestuff etc.
Major experimental instrument is originated: BP-98A rat blood pressure analyzer, Japanese Ruan Long Bioisystech Co., Ltd.
7020 type automatic clinical chemistry analyzers, HIT.
LDZ5-2 low speed autobalancing centrifuge, system in Beijing Jing founds centrifuge company.
JA1003 type electronic balance, Shanghai Hengping Science Instrument Co., Ltd..
37 DEG C of waters bath with thermostatic control, Shanghai Shiping Experiment Equipment Co., Ltd..
The full-automatic microplate reader of STAT FAX 2100, Awareness Technology Inc.USA.
95 editions 300 type semi-automatic biochemical analyzers, Dutch Rittal GmbH.
γ-911 Full automatic exempts from counting instruments, industry head office of Chinese University of Science and Technology.
GB/T14899-94 digimatic calipers, Guanglu Digital Measure-Control Co., Ltd., Guilin.
BMJ-1 biological tissue embedding machine, Tianjin Aviation Mechano-Electrical Co..
LEICARM2135 microtome, German LEICARM.
Olympus microscope and DP71 PHOTOGRAPHIC ANALYSIS system, Japan.
1 experimental technique
1.1 SHR arteria caudalis blood pressure measuring methods.
Adopt rat tail artery pulse manometry.Before pressure measurement, rat is put into the heat-preservation cylinder of 37 ± 1 DEG C, preheating about 10 minutes, is then fixed on pressure measurement on pressure-testing bench.Under rat rest state, continuous blood pressure measuring 5 times, averages as pressure measurement result.In pressure measurement process, action wants soft, avoids causing rat uneasy.Before formal experiment, adaptability pressure measurement 2 weeks.Treat that rat conforms, after blood pressure stabilization, start formally to test.
Single-dose measuring blood pressure method: Fundamentals of Measurement blood pressure is blood pressure before administration, measures the blood pressure of 1h, 3h, 6h, 12h after once daily.Every rat measures 5 blood pressures, averages.
Successive administration measuring blood pressure method: Measure blood pressure 1 time weekly, every rat measures 5 blood pressures, averages, continuous pressure measurement 4 weeks.
The index measured comprises systolic pressure (Systolic Blood Pressure, SBP), diastolic pressure (Diastolic Blood Pressure, DBP), mean arterial pressure (Mean Arterial Blood Pressure, and heart rate (Heart Reat, HR) MBP).
1.2 grouping and administrations
1.2.1 grouping
Measure the basic blood pressure of every SHR before administration, by basic blood pressure grouping, be divided into 15 groups, often organize 12 or 13, comprise model group, medicine of the present invention 1 group, medicine of the present invention 2 groups, medicine of the present invention 3 groups, medicine of the present invention 4 groups, medicine of the present invention 5 groups, medicine of the present invention 6 groups, medicine of the present invention 7 groups, medicine of the present invention 8 groups, medicine of the present invention 9 groups, medicine of the present invention 10 groups, medicine of the present invention 11 groups, medicine of the present invention 12 groups, captopril positive controls, separately establishes Normal group (WKY).
1.2.2 medication
WKY normotensive controls group and model group, gavage 0.5%CMC, administration volume is 1mL/100g body weight.
Each test medicine group: medicine 1-12 group of the present invention is 0.54g/kg/d; Positive drug captopril matched group 15mg/kg/d, gastric infusion, administration volume is 1mL/100g body weight.
Single-dose method: to measure before administration after blood pressure administration at once 1 time, dosage is the same.
Successive administration method: every day gastric infusion once, continuous 4 weeks.Survey a body weight weekly, according to body weight adjustment dosage.
1.3 sample collections and detection method
1.3.1 sample collection
Blood preparation: pharmaceutical intervention is after 4 weeks, and application chloral hydrate anesthesia, abdominal aortic blood 8ml, 37 DEG C of water-bath 30min, with the centrifugal 10min separation of serum of 3500r/min, and be sub-packed in 1.5ml Ep pipe.(2 ~ 8 DEG C deposit or-20 DEG C of freezen protective avoid multigelation).
Sick inspection specimen: dissect rat, get brain, heart, kidney, and it is fixing to put into 10% formalin solution, routine paraffin wax embeds, section, and HE dyes, om observation.
Core dirty, weigh left ventricle, full ventricular weight respectively, with kind of calliper cardiac septum thickness, left ventricular posterior wall thickness
1.3.2 detection method
Application Hitachi 7020 automatic clinical chemistry analyzer, adopts two point method to detect triglyceride (TG) concentration, cholesterol (TC) concentration, glucose (GLu) concentration.HDL-C (HDL) concentration and low-density lipoprotein cholesterol (LDL) concentration is detected by removing method.
Radioimmunology detects plasma aldosterone (ALD), plasma angiotensinogen II (AngII), Endothelin (ET), and feritin (PRL1) is active.
Double-antibody method enzyme-linked immunosorbent assay (ELISA) is adopted to detect rat Langerhans islet cellulose content.
Superoxide dismutase (SOD) adopts xanthine oxidase; Malonaldehyde (MDA) adopts thiobarbituricacidα-(TBA) colorimetry; Nitric oxide (NO) adopts nitrate reductase method.
Applying electronic digital display calliper measures cardiac septum thickness, left ventricular posterior wall thickness.Applying electronic balance weighs Left ventricular mass, whole-heartedly room myocardial Mass Measured.
1.4 statistical method
Adopt SPSS11.0 software kit to carry out statistical procedures, data are used
represent, between group, compare employing one factor analysis of variance.
2 results
The change of 2.1 experimental session rat body weights
Each group of rat body weight increases in time, and model group and WKY group rat body weight have significant difference (P<0.01).The results are shown in Table 1.
Table 1 experimental session rat body weight (g) changes
Note: compare with WKY group
##p<0.01.
[experimental example 1] medicine single-dose of the present invention is on the impact of SHR arteria caudalis blood pressure and heart rate
1. single-dose is on the impact of SHR tail systolic arterial pressure (SBP)
Model group systolic pressure is significantly higher than WKY group (P < 0.01); Single gavages medicine of the present invention, and medicine 1-12 group of the present invention all has the effect obviously reducing tail systolic arterial pressure at administration 3h, 6h, 12h, compare have significant difference (P < 0.05 ~ 0.01) with model group; Captopril group upon administration 1h, 6h, 12h obviously can reduce tail systolic arterial pressure, compares have significant difference (P < 0.05 ~ 0.01) with model group.The results are shown in Table 2.
Table 2 medicine single-dose of the present invention is on the impact of SHR tail systolic arterial pressure (mmHg)
Note: 1. compare with WKY group
##p<0.01; Compare with model group
*p<0.05,
*p<0.01.
2. in bracket, numerical value is blood pressure before this time point blood pressure * 100/ administration.
2. single-dose is on the impact of SHR arteria caudalis diastolic pressure (DBP)
Model group diastolic pressure is significantly higher than WKY group (P < 0.01); Single gavages medicine of the present invention, and medicine 1-12 group of the present invention all has the effect obviously reducing auterial diastole pressure at administration 6h, 12h, compare have significant difference (P < 0.05 ~ 0.01) with model group; Captopril group can obviously reduce auterial diastole pressure at administration 1h, 6h, 12h, compares have significant difference (P < 0.05 ~ 0.01) with model group.The results are shown in Table 3.
Table 3 medicine single-dose of the present invention is on the impact of SHR arteria caudalis diastolic pressure (mmHg)
Note: 1. compare with WKY group
##p<0.01; Compare with model group
*p<0.05,
*p<0.01.
2. in bracket, numerical value is blood pressure before this time point blood pressure * 100/ administration.
3. single-dose is on the impact of SHR arteria caudalis mean arterial pressure (MBP)
Model group mean arterial pressure is significantly higher than WKY group (P < 0.01); Single gavages medicine of the present invention, and medicine 1-12 group of the present invention all has the effect obviously reducing mean arterial pressure at administration 3h, 6h, 12h, compare have significant difference (P < 0.05 ~ 0.01) with model group; Captopril group upon administration 1h, 6h, 12h obviously can reduce mean arterial pressure, compares have significant difference (P < 0.05 ~ 0.01) with model group.The results are shown in Table 4.
Table 4 medicine single-dose of the present invention is on the impact of SHR arteria caudalis mean arterial pressure (mmHg)
Note: 1. compare with WKY group
##p<0.01; Compare with model group
*p<0.05,
*p<0.01.
2. in bracket, numerical value is blood pressure before this time point blood pressure * 100/ administration.
4. single-dose is on the impact of SHR heart rate (HR)
Single gavages medicine of the present invention to SHR heart rate substantially without impact.The results are shown in Table 5.
Table 5 medicine single-dose of the present invention is on the impact of SHR heart rate (beat/min)
Note: 1. compare with WKY group
#p<0.05; Compare with model group
*p<0.05.
2. in bracket, numerical value is heart rate before this time point heart rate * 100/ administration.
Conclusion: single gavages medicine of the present invention, medicine 1-12 group of the present invention all obviously can reduce the effect of SHR diastolic pressure and mean arterial pressure at administration 3h, 6h, 12h, on SHR heart rate substantially without impact.
[experimental example 2] medicine successive administration of the present invention 4 weeks is on the impact of SHR arteria caudalis blood pressure and heart rate
1. the successive administration impact on SHR tail systolic arterial pressure (SBP) in 4 weeks
Model group systolic pressure is significantly higher than WKY group (P < 0.01); Gavage medicine of the present invention continuously, medicine 1-12 group of the present invention all has the effect obviously reducing tail systolic arterial pressure on the 1st week in administration, compare have significant difference (P<0.05 ~ 0.01) with model group; Captopril group is starting blood pressure lowering administration the 1st week, and hypotensive effect to continue to after administration 4 weeks, with model group comparing difference remarkable (P < 0.01).The results are shown in Table 6.
Table 6 medicine successive administration of the present invention is on the impact of SHR tail systolic arterial pressure (mmHg)
Note: 1. compare with WKY group
##p<0.01; Compare with model group
*p<0.05,
*p<0.01.
2. in bracket, numerical value is blood pressure before this time point blood pressure * 100/ administration.
2. the successive administration impact on SHR arteria caudalis diastolic pressure (DBP) in 4 weeks
Model group diastolic pressure is significantly higher than WKY group (P < 0.01); Gavage medicine of the present invention continuously, medicine 1-12 group of the present invention all has the effect obviously reducing arteria caudalis diastolic pressure on the 1st week in administration, compare have significant difference (P < 0.05 ~ 0.01) with model group; Captopril group starts blood pressure lowering administration the 1st week, and hypotensive effect to continue to after administration 4 weeks, with model group comparing difference remarkable (P < 0.01).The results are shown in Table 7.
Table 7 medicine successive administration of the present invention is on the impact of SHR arteria caudalis diastolic pressure (mmHg)
Note: 1. compare with WKY group
##p<0.01; Compare with model group
*p<0.05,
*p<0.01.
2. in bracket, numerical value is blood pressure before this time point blood pressure * 100/ administration.
3. the successive administration impact on SHR arteria caudalis mean arterial pressure (MBP) in 4 weeks
Model group mean arterial pressure is significantly higher than WKY group (P < 0.01); Gavage medicine of the present invention continuously, medicine 1-12 group of the present invention all has the effect obviously reducing mean arterial pressure on the 1st week in administration, compare have significant difference (P < 0.05 ~ 0.01) with model group; Captopril group starts blood pressure lowering in administration after 1 week, and hypotensive effect to continue to after administration 4 weeks, with model group comparing difference significantly (P < 0.01).The results are shown in Table 8.
Table 8 medicine successive administration of the present invention is on the impact of SHR arteria caudalis mean arterial pressure (mmHg)
Note: 1. compare with WKY group
##p<0.01; Compare with model group
*p<0.05,
*p<0.01.
2. in bracket, numerical value is blood pressure before this time point blood pressure * 100/ administration.
4. the successive administration impact on SHR heart rate (HR) in 4 weeks
Gavage medicine of the present invention 4 weeks continuously to SHR heart rate substantially without impact.The results are shown in Table 9.
Table 9 medicine successive administration of the present invention is on the impact of SHR heart rate (beat/min)
Note: 1. compare with WKY group
##p<0.01; Compare with model group
*p<0.05,
*p<0.01.
2. in bracket, numerical value is blood pressure before this time point blood pressure * 100/ administration.
Conclusion: gavage medicine of the present invention continuously, medicine 1-12 group of the present invention all has the effect obviously reducing systolic pressure, diastolic pressure and mean arterial pressure on 1st week in administration, on SHR heart rate substantially without impact.
Following embodiment all can realize the effect of above-mentioned experimental example.
The preparation of [embodiment 1] Tibetan medicine slow releasing preparation of the present invention
Cream 50g, the Fructus Phyllanthi 180g such as ZANGJINJIER 100g, BAXIAGA 150g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 50g, Herba Corydalis 150g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng carried out respectively remove impurity, clean, mix, with 65% alcohol reflux 3 times of crude drug 10 times of weight, each extraction 2 hours, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.15; Add customary adjuvant, conveniently technique, make Tibetan medicine slow releasing preparation of the present invention.
The preparation of [embodiment 2] Tibetan medicine pill of the present invention
Cream 60g, the Fructus Phyllanthi 90g such as ZANGJINJIER 110g, BAXIAGA 60g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 60g, Herba Corydalis 60g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng are carried out remove impurity, cleaning, drying respectively, is ground into coarse powder, sieves, mixing, adds customary adjuvant, conveniently technique, makes Tibetan medicine pill of the present invention.
The discriminating of [embodiment 3] Tibetan medicine oral liquid of the present invention
Cream 60g, the Fructus Phyllanthi 90g such as ZANGJINJIER 110g, BAXIAGA 60g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 60g, Herba Corydalis 60g, Song Sheng;
By ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, the cream such as Song Sheng, Fructus Phyllanthi medical material carries out remove impurity respectively, clean, mixing, infiltration 1.5 hours is stirred with 70% ethanol of crude drug 1.5 times of weight, load in percolate pot, use crude drug 12 respectively, 10, 70% ethanol percolate extraction of 8 times of weight 3 times, collect and merge extractive liquid, filter, extracting solution is passed into absorption, washing, resolve flow velocity be 0.1-10 times of bed volume/hour D101 macroporous adsorbent resin, first wash with water, again with 10% washing with alcohol, finally resolve with 50% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.35, add customary adjuvant, conveniently technique, make Tibetan medicine oral liquid of the present invention.
The discriminating of [embodiment 4] Tibetan medicine soft capsule of the present invention
Cream 60g, the Fructus Phyllanthi 90g such as ZANGJINJIER 110g, BAXIAGA 60g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 60g, Herba Corydalis 60g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng carried out respectively remove impurity, clean, mix, with the soak by water 3 times of crude drug 10 times of weight, each decoction 2 hours, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.15, adds customary adjuvant, conveniently technique, makes Tibetan medicine soft capsule of the present invention.
The preparation of [embodiment 5] Tibetan medicine syrup of the present invention
Cream 80g, the Fructus Phyllanthi 100g such as ZANGJINJIER 120g, BAXIAGA 80g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 80g, Herba Corydalis 80g, Song Sheng;
By ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, the cream such as Song Sheng, Fructus Phyllanthi medical material carries out remove impurity respectively, clean, mixing, infiltration 1 hour is stirred with 75% ethanol of crude drug 1 times of weight, load in percolate pot, use crude drug 10 respectively, 8, 75% ethanol percolate extraction of 6 times of weight 3 times, collect and merge extractive liquid, filter, extracting solution is passed into absorption, washing, resolve flow velocity be 0.1-10 times of bed volume/hour D101 macroporous adsorbent resin, first wash with water, again with 20% washing with alcohol, finally resolve with 60% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.25, add customary adjuvant, conveniently technique, make Tibetan medicine syrup of the present invention.
The preparation that [embodiment 6] Tibetan medicine soup of the present invention is loose
Cream 100g, the Fructus Phyllanthi 130g such as ZANGJINJIER 150g, BAXIAGA 100g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 100g, Herba Corydalis 100g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng are carried out remove impurity, cleaning, drying respectively, is ground into coarse powder, sieves, mixing, make Tibetan medicine soup of the present invention and fall apart.
The discriminating of [embodiment 7] Tibetan medicine hard capsule of the present invention
Cream 100g, the Fructus Phyllanthi 130g such as ZANGJINJIER 150g, BAXIAGA 100g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 100g, Herba Corydalis 100g, Song Sheng;
By ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, the cream such as Song Sheng, Fructus Phyllanthi medical material carries out remove impurity respectively, clean, mixing, use crude drug 10 respectively, 8, 75% alcohol dipping of 6 times of weight extracts 3 times, each dipping 12 hours, collect and merge extractive liquid, filter, extracting solution is passed into absorption, washing, resolve flow velocity be 0.1-10 times of bed volume/hour D101 macroporous adsorbent resin, first wash with water, again with 20% washing with alcohol, finally resolve with 60% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.25, add customary adjuvant, conveniently technique, make Tibetan medicine hard capsule of the present invention.
The preparation of [embodiment 8] Tibetan medicine tablet of the present invention
Cream 100g, the Fructus Phyllanthi 130g such as ZANGJINJIER 150g, BAXIAGA 100g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 100g, Herba Corydalis 100g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng carried out respectively remove impurity, clean, mix, use the soak by water 3 times of crude drug 10,8,6 times of weight respectively, each decoction 1 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.25, adds customary adjuvant, conveniently technique, makes Tibetan medicine tablet of the present invention.
The preparation of [embodiment 9] Tibetan medicine drop pill of the present invention
Cream 80g, the Fructus Phyllanthi 80g such as ZANGJINJIER 180g, BAXIAGA 180g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 80g, Herba Corydalis 80g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng carried out respectively remove impurity, clean, mix, 3 times are extracted respectively by 70% alcohol dipping of crude drug 12,10,8 times of weight, each dipping 16 hours, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.35, adds customary adjuvant, conveniently technique, makes Tibetan medicine drop pill of the present invention.
The discriminating of [embodiment 10] Tibetan medicine hard capsule of the present invention
Cream 140g, the Fructus Phyllanthi 170g such as ZANGJINJIER 190g, BAXIAGA 140g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 140g, Herba Corydalis 140g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng are carried out remove impurity respectively, clean, dry, pulverize into coarse powder, sieves, mixing, adds customary adjuvant, conveniently technique, makes Tibetan medicine hard capsule of the present invention.
The discriminating of [embodiment 11] Tibetan medicine granule of the present invention
Cream 140g, the Fructus Phyllanthi 170g such as ZANGJINJIER 190g, BAXIAGA 140g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 140g, Herba Corydalis 140g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng carried out respectively remove impurity, clean, mix, use the soak by water 3 times of crude drug 12,10,8 times of weight respectively, each decoction 1.5 hours, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.35, adds customary adjuvant, conveniently technique, makes Tibetan medicine granule of the present invention.
The preparation of [embodiment 12] Tibetan medicine pill of the present invention
Cream 140g, the Fructus Phyllanthi 170g such as ZANGJINJIER 190g, BAXIAGA 140g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 140g, Herba Corydalis 140g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng carried out respectively remove impurity, clean, mix, use 75% alcohol reflux 3 times of crude drug 10,8,6 times of weight respectively, each extraction 1 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.25; Add customary adjuvant, conveniently technique, make Tibetan medicine pill of the present invention.
The preparation of [embodiment 13] Tibetan medicine controlled release preparation of the present invention
Cream 150g, the Fructus Phyllanthi 80g such as ZANGJINJIER 200g, BAXIAGA 50g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 150g, Herba Corydalis 50g, Song Sheng;
Cream, the Fructus Phyllanthi medical materials such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng carried out respectively remove impurity, clean, mix, 3 times are extracted by 65% alcohol dipping of crude drug 10 times of weight, each dipping 8 hours, collect and merge extractive liquid, filter, extracting solution is passed into absorption, washing, resolve flow velocity be 0.1-10 times of bed volume/hour cation exchange resin, first wash with water, again with 30% washing with alcohol, finally resolve with 70% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.15; Add customary adjuvant, conveniently technique, make Tibetan medicine controlled release preparation of the present invention.
The discriminating that [embodiment 14] Tibetan medicine soup of the present invention is loose
40g, the Fructus Phyllanthi 90g such as ZANGJINJIER 110g, BAXIAGA 60g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 60g, Herba Corydalis 60g, Song Sheng;
ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng etc., Fructus Phyllanthi medical material are carried out remove impurity respectively, clean, dry, pulverize into coarse powder, sieves, mixing, adds customary adjuvant, conveniently technique, makes Tibetan medicine soup of the present invention and falls apart.
The preparation of [embodiment 15] Tibetan medicine hard capsule of the present invention
100g, the Fructus Phyllanthi 130g such as ZANGJINJIER 150g, BAXIAGA 100g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 100g, Herba Corydalis 100g, Song Sheng;
ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng etc., Fructus Phyllanthi medical material are carried out remove impurity respectively, clean, mix, 3 times are extracted by 75% alcohol dipping of crude drug 10 times of weight, each dipping 12 hours, collect and merge extractive liquid, filter, extracting solution is passed into absorption, washing, resolve flow velocity be 0.1-10 times of bed volume/hour D101 macroporous adsorbent resin, first wash with water, again with 20% washing with alcohol, finally resolve with 60% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.25; Add customary adjuvant, conveniently technique, make Tibetan medicine hard capsule of the present invention.
The preparation of [embodiment 16] Tibetan medicine tablet of the present invention
180g, the Fructus Phyllanthi 170g such as ZANGJINJIER 190g, BAXIAGA 140g, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 140g, Herba Corydalis 140g, Song Sheng;
ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng etc., Fructus Phyllanthi medical material are carried out remove impurity respectively, clean, mix, with the soak by water 3 times of crude drug 10 times of weight, each decoction 1 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.25, adds customary adjuvant, conveniently technique, makes Tibetan medicine tablet of the present invention.
Claims (10)
1. the purposes of Tibetan medicinal preparation in preparation treatment essential hypertension medicine, wherein said Tibetan medicinal preparation is made up of following crude drug: 30-200 weight portion, the Fructus Phyllanthi 80-180 weight portions such as cream 50-150 weight portion or Song Sheng such as ZANGJINJIER 100-200 weight portion, BAXIAGA 50-150 weight portion, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 50-150 weight portion, Herba Corydalis 50-150 weight portion, Song Sheng.
2. purposes as claimed in claim 1, it is characterized in that, described Tibetan medicinal preparation is made up of following crude drug: 50-150 weight portion, the Fructus Phyllanthi 100-150 weight portions such as cream 80-120 weight portion or Song Sheng such as ZANGJINJIER 120-180 weight portion, BAXIAGA 80-120 weight portion, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 80-120 weight portion, Herba Corydalis 80-120 weight portion, Song Sheng.
3. purposes as claimed in claim 1, is characterized in that described Tibetan medicinal preparation is made up of following crude drug: 100 weight portions, Fructus Phyllanthi 130 weight portions such as cream 100 weight portion or Song Sheng such as ZANGJINJIER 150 weight portion, BAXIAGA 100 weight portion, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.) 100 weight portion, Herba Corydalis 100 weight portion, Song Sheng.
4. purposes as claimed in claim 1, it is characterized in that, described Tibetan medicinal preparation is pill, tablet, capsule, oral liquid, syrup, granule, powder, drop pill, slow releasing preparation or controlled release preparation.
5. the purposes as described in any one of Claims 1 to 4, wherein said treatment essential hypertension is systolic pressure, diastolic pressure and the mean arterial pressure treatment essential hypertension by reducing primary hypertension patient.
6. the preparation method of Tibetan medicinal preparation according to claim 1, comprises cream or the Song Sheng etc. such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng, the remove impurity respectively of Fructus Phyllanthi crude drug, cleaning, drying, is ground into coarse powder, sieves, mix and get final product.
7. the preparation method of Tibetan medicinal preparation described in claim 1, comprise and cream or Song Sheng etc., the Fructus Phyllanthi crude drug such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng are carried out remove impurity, clean, mixing respectively, with 50-90% alcohol reflux 1-3 time of crude drug 5-15 times of weight, each extraction 0.5-2.5 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.0-1.5; Or extracting solution passed into absorption, washing, the flow velocity of resolving are 0.1-10 times of bed volume/hour D101 or D101B or XDA-1 or XDA-1B or HPD-300 macroporous adsorbent resin or cation exchange resin, first wash with water, again with 10-30% washing with alcohol, finally resolve with 50-70% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.0-1.5; Add the adjuvant pharmaceutically accepted, make described Tibetan medicinal preparation.
8. the preparation method of Tibetan medicinal preparation described in claim 1, comprise cream or the Song Sheng etc. such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng, the remove impurity respectively of Fructus Phyllanthi medical material, clean, mix, stir with the 50-90% ethanol of crude drug 0.5-1.5 times of weight and infiltrate 0.5-2 hour, load in percolate pot, with 50-90% ethanol percolate extraction 2-4 time of crude drug 5-15 times of weight, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.0-1.5; Or extracting solution passed into absorption, washing, the flow velocity of resolving are 0.1-10 times of bed volume/hour D101 or D101B or XDA-1 or XDA-1B or HPD-300 macroporous adsorbent resin or cation exchange resin, first wash with water, again with 10-30% washing with alcohol, finally resolve with 50-70% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.0-1.5; Add the adjuvant pharmaceutically accepted, make described Tibetan medicinal preparation.
9. the preparation method of Tibetan medicinal preparation described in claim 1, comprise cream or the Song Sheng etc. such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng, the remove impurity respectively of Fructus Phyllanthi medical material, clean, mix, extract 2-4 time by the 50-90% alcohol dipping of crude drug 5-15 times of weight, each dipping 8-16 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.0-1.5; Or extracting solution passed into absorption, washing, the flow velocity of resolving are 0.1-10 times of bed volume/hour D101 or D101B or XDA-1 or XDA-1B or HPD-300 macroporous adsorbent resin or cation exchange resin, first wash with water, again with 10-30% washing with alcohol, finally resolve with 50-70% ethanol, collect ethanol, reclaim ethanol and be condensed into the concentrated solution that relative density is 1.0-1.5; Add the adjuvant pharmaceutically accepted, make described Tibetan medicinal preparation.
10. the preparation method of Tibetan medicinal preparation described in claim 1, comprise and cream or Song Sheng etc., the Fructus Phyllanthis such as ZANGJINJIER, BAXIAGA, Lagotis clarkei Hook. F (Lagotis brevituba Maxim.), Herba Corydalis, Song Sheng are carried out remove impurity, clean, mixing respectively, with soak by water 2-4 time of crude drug 5-15 times of weight, each decoction 0.5-2.5 hour, collect and merge extractive liquid, filter, extracting solution is condensed into the concentrated solution that relative density is 1.0-1.5, add the adjuvant pharmaceutically accepted, make described Tibetan medicinal preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410515691.9A CN104274583A (en) | 2012-08-15 | 2012-08-15 | Tibetan medicinal preparation for treating essential hypertension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410515691.9A CN104274583A (en) | 2012-08-15 | 2012-08-15 | Tibetan medicinal preparation for treating essential hypertension and preparation method thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102901427A Division CN102772546A (en) | 2012-08-15 | 2012-08-15 | Tibetan medicine preparation for treating essential hypertension and preparation method of Tibetan medicine preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104274583A true CN104274583A (en) | 2015-01-14 |
Family
ID=52250244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410515691.9A Pending CN104274583A (en) | 2012-08-15 | 2012-08-15 | Tibetan medicinal preparation for treating essential hypertension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104274583A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109172731A (en) * | 2018-07-27 | 2019-01-11 | 三亚海王海洋生物科技有限公司 | A kind of preparation method and applications of oyster compound extract that treating cough, essential hypertension and apoplexy |
| CN114984141A (en) * | 2022-07-01 | 2022-09-02 | 西藏藏医药大学附属医院 | Tibetan medicine composition for promoting blood circulation to remove blood stasis and promoting blood circulation to regulate qi, and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391081A (en) * | 2008-11-11 | 2009-03-25 | 南京同仁堂药业有限责任公司 | Medicine composition for treating qi and blood derangement of essential hypertension and preparation method thereof |
| CN102590430A (en) * | 2012-01-17 | 2012-07-18 | 西藏奇正藏药股份有限公司 | Method for detecting liuwei caragana preparation |
-
2012
- 2012-08-15 CN CN201410515691.9A patent/CN104274583A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391081A (en) * | 2008-11-11 | 2009-03-25 | 南京同仁堂药业有限责任公司 | Medicine composition for treating qi and blood derangement of essential hypertension and preparation method thereof |
| CN102590430A (en) * | 2012-01-17 | 2012-07-18 | 西藏奇正藏药股份有限公司 | Method for detecting liuwei caragana preparation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109172731A (en) * | 2018-07-27 | 2019-01-11 | 三亚海王海洋生物科技有限公司 | A kind of preparation method and applications of oyster compound extract that treating cough, essential hypertension and apoplexy |
| CN114984141A (en) * | 2022-07-01 | 2022-09-02 | 西藏藏医药大学附属医院 | Tibetan medicine composition for promoting blood circulation to remove blood stasis and promoting blood circulation to regulate qi, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1239187C (en) | Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method | |
| WO2007009291A1 (en) | A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof | |
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| TWI275397B (en) | Herbal composition, use thereof in protection of endothelial cell and in anti-inflammation, and preparation method thereof | |
| CN102772546A (en) | Tibetan medicine preparation for treating essential hypertension and preparation method of Tibetan medicine preparation | |
| CN102512482A (en) | Euonymus alatus extract, blood-sugar-reducing activity thereof and application of euonymus alatus extract to preparation of products for reducing blood sugar | |
| KR100811873B1 (en) | An anti-rheumatism medicament and method to prepare thereof | |
| KR101431788B1 (en) | A Chinese medicine composition and its preparation method and drug application in the treatment of kidney stones | |
| CN104274583A (en) | Tibetan medicinal preparation for treating essential hypertension and preparation method thereof | |
| CN106177434A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN107744571B (en) | Pharmaceutical composition for improving vascular endothelial dysfunction and preparation method and application thereof | |
| TWI438001B (en) | Plant extract for treating diabetes and process for making same | |
| CN106177479A (en) | A kind of Hyperglycemic health care compositions comprising Herba Dendrobii and Rhizoma Polygonati Odorati | |
| CN103239618B (en) | Traditional Chinese medicine composition for treating chronic hepatitis and cirrhosis and preparation method thereof | |
| CN109248188A (en) | A kind of preparation method and applications of goldspink root extract | |
| CN110742935B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating chronic alcoholic steatohepatitis | |
| CN103285072B (en) | Comprise extract and the medical usage thereof of hyperin | |
| CN107625796B (en) | Pharmaceutical composition containing radix angelicae and application thereof | |
| TW201247212A (en) | Use of ginseng flower extract to prevent or cure diseases or symptoms caused by abnormally high blood uric acid concentration | |
| CN101874830B (en) | New application of golden thread processed product | |
| CN105920066A (en) | Applications, as well as preparation method and preparation of vernonia amygdalina extract | |
| CN101766683B (en) | Salvia dispersible tablet and application thereof | |
| CN100434092C (en) | Prescription containing sweet clover component and its formulation | |
| CN100589800C (en) | Chinese medicine preparation of total coumarins extract from peu cedanum praeruptorum dunn, and its preparing method and use | |
| CN100512827C (en) | Chinese medicine tablet of total coumarins extract from peucedanum praeruptorm and its preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150114 |
|
| RJ01 | Rejection of invention patent application after publication |